Pneumatic vitreolysis for relief of vitreomacular traction

Purpose: To evaluate the outcome of perfluoropropane (C 3 F 8) gas injection for symptomatic vitreomacular traction (VMT) with or without Stage 2 macular hole (MH). Methods: A retrospective review of eyes with VMT treated with 0.3 mL of C 3 F 8 gas was performed. Patients avoided the supine position until gas resolution. Patients with small MH maintained partial face-down positioning. Results: Forty-nine consecutive patients (50 eyes) with symptomatic VMT underwent pneumatic vitreolysis between 2010 and 2016. A posterior vitreous detachment developed in 43 eyes (86.0%) after a single gas injection, at a median of 3.0 weeks. Twenty-eight of 35 eyes (80.0%) with VMT only and all 15 eyes (100%) with a small Stage 2 MH developed a posterior vitreous detachment, with MH closure in 10 of 15 eyes (66.7%). Median baseline and last best spectacle-corrected visual acuities were 20/50 and 20/40, respectively (P < 0.001). Mean follow-up time was 11.1 ± 9.9 months. Rate of posterior vitreous detachment was reduced with presence of diabetes mellitus (25%) and with thick cellophane membrane (50%). Univariate analysis showed increased VMT release for eyes with VMT extent within 1 disk area (χ 2 = 13.1, P = 0.002), eyes with absence of diabetes mellitus (χ 2 = 8.8, P = 0.007), and eyes with Stage 2 MH (χ 2 = 5.47, P = 0.019); there was a trend between success and lack of thick cellophane membrane (χ 2 = 3.32, P = 0.068). Results using logistic regression also showed younger age (P = 0.012), followed by better baseline best spectacle-corrected visual acuity (P = 0.044), lack of diabetes mellitus (P = 0.077), and female gender (P = 0.045) to be predictors of increased VMT release. One VMT-only eye formed a MH and another VMT-only eye developed a retinal detachment. Both eyes responded to vitrectomy. Conclusion: Pneumatic vitreolysis with limited face-down position is a viable option for treating VMT with few adverse events. More studies are needed to elucidate its indications, benefits, and risks.